Top 5 This Week

Related Posts

Rachel Reeves confident Gulf trade deal can be done ‘very soon’; European shares ease from record highs – business live | Business

Reeves confident Gulf trade deal can be done ‘very soon’

Rachel Reeves has expressed confidence that a trade deal with Gulf countries can be done quickly, saying she had “really good” meetings in Riyadh.

“I am really confident we can get that deal over the line,” she said at Saudi Arabia’s flagship investment summit held in the Saudi capital, adding she was hopeful that the agreement could be reached “very soon”.

The chancellor hopes to deepen the UK’s relationship with a state that has been widely criticised for human rights abuses.

Reeves, who is the first UK chancellor to visit the region in six years, wants to use the trip to speak with her counterparts from Bahrain, Kuwait and Qatar to advance a trade deal with the Gulf Cooperation Council (GCC), a six-nation group.

British administrations have sought to reach an agreement with the GCC after Britain left the European Union in 2020.

Reeves is also expected to meet senior Saudi royals, members of Donald Trump’s administration and business figures while in Saudi Arabia.

Last year Saudi Arabia’s Public Investment Fund bought a 15% stake in London’s Heathrow Airport from Spanish construction company Ferrovial, and Britain expects further investment announcements this week.

New state-owned airline Riyadh Air, which ordered 25 partly British-built Airbus A350 aircraft in June, has announced its inaugural flight will be to Heathrow.

Trade minister Chris Bryant told parliament this month that talks with the GCC were at “an advanced stage”, despite concerns from trade unions close to the Labour Party about poor rights for workers and other perceived abuses in the region.

The Treasury estimates a Gulf trade deal would add £1.6bn a year to UK economic output – equivalent to about 0.06% of annual gross domestic product.

The Treasury said on Sunday that Reeves would be “honest over areas of divergence and cultural differences” during her conversations with her Gulf counterparts.

Share

Updated at 

Key events

Head of Office for Life Sciences says ‘good US deal’ would ‘quickly resolve’ standoff with pharma

Steve Bates, executive chairman of the Office for Life Sciences, said “a good US deal” would “quickly resolve” the issue of a lack of confidence of big pharmaceutical companies such as AstraZeneca and MSD in the UK, and its impact on investment decisions.

Quizzed by MPs on the science committee, Bates, who took up his new job at OLS in September after running the BioIndustry Association for 13 years, said:

So I think a good deal with the USA can quickly resolve it, is the simple answer for that.

I’m saying that if the UK can get a fantastic domestic business environment allied to access to global markets, that’s a fantastic base from which any companies would want to grow for the world.

MSD, known as Merck in the US, AstraZeneca and other big pharma companies have scrapped or paused investments in the UK, while ramping up investments in the US. The UK head of Novartis called Britain “largely uninvestable” as negotiations between the industry and UK government over a new pricing agreement broke down in late August.

Meanwhile, Donald Trump has been putting pressure on drugmakers to invest more in the US, and to cut drug prices, or face trade tariffs.

This means any UK decisions on higher drug pricing and NHS spending are tied to a deal with the US. Varun Chandra, business adviser to Keir Starmer, has been leading negotiations with officials in Washington.

Sir Patrick Vallance, former GSK executive, now science minister. Photograph: Reuters

Science minister Patrick Vallance, a former GSK executive, said in front of the same committee that “some degree of price increase is inevitable in the UK,” referring to higher NHS spending on new medications that the pharma industry has long called for.

I think for brand new, innovative medicines, it’s likely there will be some price increase.

If you go back to 2015 the spend on medicines was about 12% [of total NHS spending] if you go back earlier, it was higher, it was about 14%. It’s now about 9%. So there is a possibility of increasing percentage spend.

Share

Updated at 



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular Articles